The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Luminex
Research Funding - Lilly; Pfizer
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
 
Komal L. Jhaveri
Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical
 
Rinath Jeselsohn
No Relationships to Disclose
 
Elgene Lim
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Travel, Accommodations, Expenses - Lilly
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
J. Thaddeus Beck
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); DSi (Inst); Genentech/Roche (Inst); Lilly (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen
Honoraria - Eisai; Lilly; Macrogenics; Polyphor
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech
Speakers' Bureau - Lilly
Research Funding - Eisai (Inst); Lilly (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Lilly; Macrogenics; Polyphor
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Novartis; Sermonix Pharmaceuticals
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Sermonix Pharmaceuticals
 
Manali A. Bhave
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Merck
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Ax's Consulting; Byondis; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; ISSECAM; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks
Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim España (Inst); Bristol-Myers Squibb (BMS) (Inst); Cytomx Therapeutics (Inst); Daiichi Sankyo (Inst); Genentech (Inst); German Breast Group (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); International Breast Cancer Study Group (Inst); Lilly (Inst); Macrogenics (Inst); MedSIR (Inst); Menarini (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Novartis Farmacéutica (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen-Cilag; MedSIR; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Sanofi; Seagen; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Tarek Meniawy
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Timothy Larson
No Relationships to Disclose
 
Cynthia X. Ma
Consulting or Advisory Role - Agendia; AstraZeneca; Athenex; Bayer; Biovica; Eisai; Gilead Sciences; Inivata; Jacobio; Natera; Novartis; Olaris; Philips Electronics; Puma Biotechnology; Sanofi; Seagen
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Javier García-Corbacho
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - BMS
 
Shanshan Cao
Employment - Lilly
 
Shawn T. Estrem
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Jennifer L. Milata
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Bastien Nguyen
Employment - Loxo/Lilly
 
Muralidhar Beeram
Honoraria - Genentech (Inst); Johnson & Johnson (Inst)
Consulting or Advisory Role - Bayer (I); Merck (I); Novartis (I); Seagen (I)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
Research Funding - Agios (Inst); AstraZeneca (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Phoenix Molecular Designs (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Genentech; Merck